Newly Established Bio Diagnostics Company Investment Opportunity in United States

Successful Phase I & II clinical trials proved its efficacy to be 5x greater than the US standard diagnostic treatment. The Nuclear medicine and molecular imaging (NMMI) technology was designed to focus on pulmonary diseases. Our product development growth plan will expand its worldwide patient care to include a TB derivative, lung-cancer, sickle-cell, and others planned for commercialization and distribution. Our valuation was recently updated by Marquee Equity to reflect $223m, due to the projected monthly and yearly patient treatments administered by the various governments and NGO sponsors.
Based on an independent market analysis by DyoDelta Biosciences in London, our primary pulmonary disease focus is projected to average $78m/yr. , over a five year period, from pharma licensing agreement contracts. The US operational facility is a leased space. The manufacturing of the diagnostics will be in accordance with WHO standards and related FDA radiopharmceutical requirements. To date, the business has been self-funded. Our global initiative will be financed through an offering by Marquee Equity in India, in addition to a digital asset capital raise through INX, which operates in 73 countries and is regulatory approved and SEC-compliant.
At this time through Dec, 31, '23, we are offering a $3m investor participaition, for early-stage investors. In January '24, Marquee will increase the offering to $30m, to be compliment by the INX digital asset raise for up to $50m.
For institutional type investor relationships, an opportunity is available to be a stakeholder in the holding company.